China's marine biomedicine has huge room for growth

1. There are many pain points in the development of China's marine biomedical industry, and technological breakthroughs are urgently needed

The marine biomedicine industry refers to the production of marine biochemical drugs, health products and genetic engineering drugs using marine organisms as raw materials or extracting effective ingredients, such as genes, fermentation engineering drugs, genetic engineering vaccines, Antibiotics, vitamins, Blood Products, etc. . The research and industrialization of marine medicines and marine biological products has now become a hotspot for competition among marine powers.

However, compared with countries with developed marine biomedicine industries such as the United States and France, my country's marine biomedicine industry has more pain points. For example, due to the longer cycle and higher cost of developing marine drugs, for pharmaceutical companies, the risk of developing marine drugs is greater than other drugs.

The international drug research and development cycle is generally 10-15 years, and the research and development cycle of marine drugs currently on the market is generally more than 20 years, which means that marine biomedicine development companies need to bear higher risks. In addition, issues such as technological level, capital investment, and industrialization bottlenecks restrict the development of my country's marine biomedical industry.

In addition, although the technical level of my country's marine biomedicine is constantly developing, the technical level of my country's marine biomedicine industry is still far behind the United States and France. Judging from the number of marine biomedical patent applications and publications in my country in recent years, the overall number of applications is not high, only 17 in 2019. In general, the development of marine biomedical technology in my country is still in its infancy, and the technological activity is relatively low. It can be seen that my country's marine biomedicine industry still has a long way to go in the future, especially in the field of marine biomedical technology.

2. Favorable policy promotion, provinces increase industry investment

In order to promote the development of China's marine biopharmaceutical industry, my country has successively introduced a number of encouragement and support policies under the various development pain points of my country's marine biomedical industry. For example, in May 2017, the "Thirteenth Five-Year Plan for National Marine Economic Development" mentioned that it will focus on supporting innovative marine medicines with independent intellectual property rights, broad market prospects, and health and safety, and developing modern marine traditional Chinese medicines with ethnic characteristics. product.

In June 2019, Qingdao supported the "Blue Drug Bank" development plan to establish a 5 billion yuan "China Blue Drug Bank Development Fund". In April 2020, the "Guiding Opinions on Promoting the High-quality Development of Trade" pointed out that it is necessary to promote the first breakthroughs in key areas such as high-end equipment manufacturing, information technology, and biomedicine.

With the support of these policies and the promotion of market demand, innovative marine drugs with independent intellectual property rights, health and safety, green and high efficiency will usher in good development opportunities. With the rise of the blue economy boom, Shandong, Guangdong, Zhejiang, Jiangsu, Fujian and other coastal provinces have increased their investment in the marine biomedical industry.

Shandong has set up a development fund of 5 billion yuan for the "China Blue Drug Bank" and built 6 product development platforms including modern marine medicine and modern marine Chinese medicine. Track the development trend of international biotechnology, and use high-tech and modern synthetic technologies such as genetic engineering, cell engineering, enzyme engineering, Biochemical Engineering, biomedicine, etc. to conduct marine biomedicine research and development. Relying on scientific research institutions such as Sun Yat-sen University and the South China Sea Institute of Oceanology of the Chinese Academy of Sciences, Guangdong has built a number of scientific and technological research and development platforms with strong competitiveness and high added value.

3. The market scale grows, and the future growth space is large

With the support of policies such as the national "blue economy" strategy and the continuous improvement of marine biological extraction technology, my country's marine biological medicine industry has continued to develop and is the fastest growing field in the marine industry in the past decade. According to data from the State Oceanic Administration, in 2019, my country's marine biomedicine industry achieved an added value of 44.3 billion yuan, an increase of 8.0% year-on-year, and there is plenty of room for future growth.

The research and development of marine biopharmaceuticals requires large investment, high risk, and long cycle. Government support is of great significance to the development of my country's marine biopharmaceutical industry. With the development of marine economy, continuous improvement of biotechnology and government policy support, my country's marine medicine market will usher in rapid development in the future.